Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
These CellCarrier Ultra microplates for high content imaging applications are ultra-low attachment (ULA) treated and are available in black in a 384-well format. The CellCarrier Ultra HCS microplates benefit from a film bottom made of cyclic olefin, a plastic that has glass-like optical properties, providing superior image quality and also good cell adherence. They have an ultra-low plate bottom (0.2mm) for better well access when using water immersion and high NA objectives, and a new design, low profile polystyrene lid for reduced evaporation. Pack of 10.
Drawing on many years of experience in High-Content Screening, PerkinElmer’s expert team has developed and validated the CellCarrier™ Ultra line of microplates. These microplates have been engineered to deliver both perfomance and superior images for high-content applications.
CellCarrier Ultra plates are part of a range of microplates for high content applications, and belong to our complete solution for high content imaging that includes the Operetta® High Content Imaging and Opera Phenix™ High Content Screening Systems, software, and automation.
|Detection Method||Confocal Imaging, Fluorescence, High Content Imaging|
|Product Brand Name||CellCarrier|
|Unit Size||10 plates|
Find out about our range of integrated solutions for drug discovery screening in this e-brochure.
Our screening solutions for high-throughput screening, phenotypic screening and data analysis help to streamline drug discovery workflows in labs across the globe. Our portfolio includes automated liquid handling, assays and reagents, imaging and detection systems, and informatics.
Working independently or together, with our solutions you can achieve consistent and accurate results. By accelerating the identification and characterization of effective and safe drug candidates, the PerkinElmer portfolio enables you to optimize efficiency in your lab and deliver more actionable, real-world results.
Download the brochure to learn more about how we can partner with you so that you can discover smarter, more effective, data-driven breakthroughs in the critical screening stages of drug discovery and development.